natgillin/translations-raw huggingface dataset:
A compound of the invention in free or salt form and, where possible, in pharmaceutically acceptable acid addition salt form for the treatment of a disease or condition in which vanilloid receptor plays a role or is implicated; 
(2) spoj formule (1) ili (a) u slobodnom obliku ili u obliku soli 1, gdje je to moguće, u obliku farmaceutski prihvatljive kiselinske adicijske soli za liječenje bolesti ili stanja u kojem neku ulogu ima vaniloid receptor ili je on u to uključen;
The solid oral extended release pharmaceutical dosage form of anyone of claims 1, 3, 5 and 7, wherein the active agent is oxycodone hydrochloride and wherein a dosage form comprising 10 mg of oxycodone hydrochloride when tested in a comparative clinical study is bioequivalent to a reference tablet containing 10 mg of oxycodone hydrochloride in a matrix formulation containing: 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema zahtjevu 1, naznačen time da oblik doziranja sadrži 10 mg oksikodon hidroklorida kada je ispitivan u komparativnoj kliničkoj studiji je sa referentnom tabletom koja sadrži 10 mg oksikodon hidroklorida u matričnoj formulaciji koja sadrži:
Gemcitabine hydrochloride (2′,2′-difluoro-2′-deoxycytidine hydrochloride) is an anti-tumor agent, with known antiviral action, that is currently produced and marketed as Gemzar®; a lyophilised, powder formulation for treatment of various cancers. 
Gemcitabin-hidroklorid (2',2'-difluor-2'-deoksicitidin-hidroklorid) je protutumorsko sredstvo, s poznatim protuvirusnim djelovanjem, kojeg se trenutno proizvodi i prodaje kao Gemzar*; to je liofilizirana, praškasta formulacija za liječenje različitih oblika raka.
The method of claim 1, wherein the genotype of the E. coli lacks degP and prc genes and harbors a mutant spr gene. 
Postupak prema zahtjevima 5 ili 6, naznačen time, da genotipu bakterije £. coli nedostaju geni degP i prc, ali uzgaja mutirajući gen spr.
A compound according to claim 5 wherein R2 is selected from the group consisting of 3-fluoro-2-methylphenyl, 2-trifluoromethyloxyphenyl, 2-chloro-3-fluorophenyl, 2-ethylphenyl or 2-phenyloxyphenyl. 
Spoj u skladu s patentnim zahtjevom 5, naznačen time što se R2 bira iz skupine koju čine 3-fluor-2-metilfenil, 2-trifluormetiloksifenil, 2-klor-3-fluorfenil, 2-etilfenil ili 2-feniloksifenil.
having a competitive inhibitory activity against M30 antibody for the binding to B7-H3, wherein M30 antibody comprises a heavy chain which comprises an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO: 51 and a light chain which comprises an amino acid sequence consisting of residues 23 to 235 of SEQ ID NO: 53. 
(d) da ima kompetitivnu inhibitornu aktivnost za M30 antitijelo za vezivanje za B7-H3, gdje M30 antitijelo sadrži teški lanac koji sadrži aminokiselinsku sekvencu koja se sastoji od aminokiselinskih ostataka 20 do 471 sa SEK ID BR: 51 i laki lanac koji sadrži aminokiselinsku sekvencu koja se sastoji od ostataka 23 do 235 sa SEK ID BR: 53.
A method for treating a viral infection, comprising administering to a human subject in need thereof a therapeutically effective amount of a compound having the following structure: or a pharmaceutically acceptable salt or hydrate thereof; wherein the virus is selected from the group consisting of viruses of the orthomyxoviridae, bunyaviridae, flaviviridae, and filoviridae families. 
[image] pri čemu A je NH2; i B je H; ili njegova farmaceutski prihvatljiva sol ili hidrat, namjenjen liječenju, prevenciji ili suzbijanju virusne infekcije kod subjekta; gdje virusna infekcija sadrži: virus odabran iz skupine koja se sastoji od virusa iz obitelji virusa orthomyxoviridae, paramyxoviridae, arenaviridae, bunyaviridae, flaviviridae, filoviridae, togaviridae, picornaviridae, i coronaviridae; ili
A rapamycin carbohydrate derivative having the structure of formula (I): wherein 
Ugljikohidratni derivat rapamicina strukture formule (I): o naznačen time da:
A polypeptide that consists of at least one, at least two, at least three or all four of amino acid sequences SEQ ID NO: 5, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4, wherein the polypeptide elicits an antibody specific for sclerostin of SEQ ID NO: 1 when the polypeptide is administered to an animal. 
Polipeptid koji se sastoji od aminokiselinskih odsječaka SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 i SEQ ID NO: 5, naznačen time, da su odsječak SEQ ID NO: 2 I odsječak 4 spojeni disulfidnom vezom na aminokiselinskim položajima 57 i 111 s referencom na odsječak SEQ ID NO: 1 a odsječci SEQ ID NO: 3 i 5 su spojeni
The pharmaceutical formulation according to claim 1 wherein the formulation is about 0.25-0.8% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; about 62-77% metformin hydrochloride; about 3-10% hydroxypropyl cellulose; about 5-21% microcrystalline cellulose; about 5-9% sodium starch glycolate or about 5-8% hydroxypropyl cellulose, low substituted; and about 0.6-1.4% magnesium stearate. 
Postupak prema zahtjevu 24 ili zahtjevu 25, naznačen time što farmaceutska formulacija sadrži 0.25-0.8% dapagliflozina ili dapagliflozin (S) propilen glikol hidrata; 62-77% metformin hidroklorida; 3-10% hidroksipropil celuloze; 5-21% mikrokristalne celuloze; 5-9% natrijevog škrob glikolata; i 0.6-1.4% magnezijevog stearata.
Compounds II can also be prepared by reacting compound XIII with an alkyl metal species followed by reaction with disulfide XIV, e.g. via the method reported by Carreno et al. Tetrahedron, 1991, 47, 605-614. 
Spojevi II mogu se pripraviti 1 reakcijom spoja XIII s nekom vrstom alkilnog metala 1 potom reakcijom s bisulfidom XIV, npr. na način opisan u Carreno i sur, Tetrahedron 1991., 47, 605-614.
One embodiment of the present invention pertains to compounds of Formula (I) wherein R1 is selected from the group consisting of H, halogen, hydroxy, C1-4 haloalkyl, C1-4 alkyl, C1-4 alkoxy, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkylthio, and CoA haloalkoxy. 
Jedan oblik prikazanog izuma se odnosi na spojeve Formule (I) gdje R, je izabran iz skupine koju čine H, halogen, hidroksi, Ci.4 haloalkil, C,.4 alkil, C,4 alkoksi, C>.4 alkenil, C2.4 alkinil, C,.4 alkiltio, te C,.4 haloalkoksi.
One magnetized surface of this material serves to transfer indicia, such as a design or image, to a wet coating on a substrate, such as a sheet or web. 
Jedna magnctizirana površina takvog materijala služi za prenošenje oznakc, poput uzorka ili slike, na vlažni premaz nancsen na podlogu, poput lista papira ili tkanine.
Heating a sample to a temperature that is much higher (e.g. 200 K higher) than the crystal formation will gradually turn the sample from the tetragonal phase to a monoclinic phase. 
Zagrijavanje uzorka na temperaturu koja je mnogo viša (npr., 200 K viša) od temperature tvorbe kristala će postupno pretvoriti uzorak iz tetragonske faze u monoklinsku fazu.
Sugar replacement composition according to one of the preceding claims, further comprising an ingredient selected from the group consisting of calcium, magnesium, potassium, phosphorus, vitamin C, vitamin B, vitamin A, vitamin K and vitamin E, selenium, iron, zinc or a combination thereof. 
Sastavina koja zamjenjuje šećer iz jednog od prethodnih patentnih zahtjeva, koja nadalje sadržava sastojak odabran iz skupine koju čine kalcij, magnezij, kalij, fosfor, vitamin C, vitamin B, vitamin A, vitamin K i vitamin E, selen, željezo i cink, ili njihove kombinacije.
The paper of embodiment 9, wherein the paper is in the form of a packaging material, or an insulating material. 
Papir u skladu s patentnim zahtjevom 9, pri čemu je papir u obliku ambalaže ili izolacijskog materijala.
Example 2: Preparation of the concentrated multi-component 
Broj objave europskog patenta:
Thus, when performing multiple injections, retraction of the needle means and rotation of the outer sheath is required. 
Dakle, kada se izvodi višestruko injektiranje, zahtijeva se izvlačenje sredstva za probadanje i rotacija vanjskog omotača.
A method of treating a human subject suffering from hepatocellular carcinoma, comprising administering to said subject an effective amount of the double-stranded short interfering nucleic acid (siNA) molecule of claim 1 and an anti-cancer agent, thereby treating the human subject suffering from hepatocellular carcinoma. 
Kombinacija, naznačen time, da sadržava molekulu s dvolančanom kratkom interferirajućom nukleinskom kiselmom (siNA) u skladu s patentnim zahtjevom 1 i sredstvo protiv raka za upotrebu u postupku liječenja hepatocelularnog karcinoma.
* and wherein said alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene can be unsubstituted or substituted with Z; 
* i pri čemu navedem alkil, alkenil, alkinil, aril, heterocikl, arilalkilen, arilalkenilen, arilalkinilen, heterociklički-alkilen, heterociklički-alkenilen ili heterociklički-alkinilen može biti nesupstituiran ili supstituiran sa Z;
The therapeutic agent or prophylactic agent according to claim 36, wherein the acid-related diseases or symptoms are gastroesophageal reflux disease or symptomatic gastroesophageal reflux disease. 
Terapijsko sredstvo ili profilaktičko sredstvo u skladu s patentnim zahtjevom 36, naznačeno time, da su bolesti ili simptomi povezani s kiselinom bolest gastroezofagealnog refluksa ili simptomatična bolest gastroezofagealnog refluksa.
The slurry was stirred until dissolution was observed. 
Mulj se miješa do otapanja.
The coating of claim 10 or 11, wherein the coating is capable of being modified to a conductive coating with sacrificial corrosion protection. 
Sastav obloge iz patentnog zahtjeva 7, pri čemu se obloga može preoblikovati u provodljivu oblogu s potrošnom zaštitom od korozije.
Process for preparing the compound of the formula (II) according to claim 3, comprising reacting the compound of the formula (I) in a solvent with aqueous sodium hydroxide solution, optionally with the addition of a base. 
Postupak za pripravu spoja formule (II) prema zahtjevu 3, naznačen time da spoj s formulom (1) reagira u otapalu s vodenom otopinom natrijevog hidroksida, ako je prikladno uz dodavanje baze.
has a mutation or deletion in the gene encoding factor VIII; 
(a) ima mutaciju ili deleciju u genu koji kodira faktor VIII;
provided that no more than one R41 is (C1-6)alkyl substituted with C1-6alkylamino or (C1-6alkyl)2amino; aminosulfonyl; formylamino; aminocarbonyl; C1-6alkylaminocarbonyl; (C1-6alkyl)2aminocarbonyl; heterocyclylcarbonyl; hydroxy; carboxy; or a phenyl- or heteroaryl-containing substituent; is a substituent on a nitrogen atom of ring A selected from the group consisting of hydrogen and C1-4alkyl; 
Crsalkilaminokarbonil; (C;.4alkil)aminokarbonil; heterociklilkarbonil pri čemu heterociklil je 5-7 člani prsten koji sadrži dušik i navedeni heterociklil je spojen na karbonil ugljik preko atoma dušika; karboksi; i cijano: uz uvjet da ne više od jedan R'' supstituent je formilamino, aminokarbonil, C,yalkilaminokarbonil, (Crgalkil),aminokarbonil, heterociklilkarbonil, hidroksi, karboksi ili supstituent koji sadrži fenil; je vodik ili metil;
The motorized buoy of claim 1, wherein the visual indicator (120) is a flag. 
Motorizirana bova prema zahtjevu 1, naznačena time, da vizualni indikator (120) je zastava.
a first QAM mapper configured to demultiplex the bit interleaved Layer 1 signaling data into cell words and map the cell words into constellation values,wherein the transmitter is configured to process Layer 1 signaling data, wherein the Layer 1 signaling data include Data_Slice_num_PLP information indicating a number of PLPs carried within an associated data slice, the data slice being a group of OFDM cells carrying at least one PLP in a certain frequency sub-band. The transmitter of paragraph 1, further comprising: a second BCH encoder configured to BCH-encode PLP data to generate an error protected data; 
Prijenosnik iz patentnog zahtjeva 1 nadalje obuhvaća: drugi BCH koder konfiguriran za BCH-kodiranje PLP podatka zbog stvaranja podataka zaštićenih od pogreške; drugi LDPC koder konfiguriran za LDPC-kodiranje BCH kodiranih PLP podataka; drugi dio za umetanje bitova konfiguriran za umetanje bitova u LDPC kodirane PLP podatke; drugi QAM maper konfiguriran za demultipleksiranje umetnutih PLP podataka u stanične riječi i za mapiranje staničnih riječi u konstelacijske vrijednosti; 1 dio za umetanje vremena-frekvencije konfiguriran za umetanje vremena-frekvencije u mapirane konstelacijske vrijednosti.
A bispecific antibody or antibody fragment thereof that specifically binds to IL-13 and IL-4, wherein the bispecific antibody or antibody fragment thereof contains two light chains with the structure N-VLhB-B13-inker-VLh8D4-8-CL-C and two heavy chains with the structure N-VHhB-B13-linker-VHh8D4-8-CH1-CH2-CH3-C, wherein CL is the light chain constant region, VLhB-B13 is a humanized light chain variable domain of anti IL-13 antibody B-B13, YLh8D4-8 is a humanized light chain variable domain of anti IL-13 antibody B-B13, VHhB-B13 is a humanized heavy chain variable domain of anti IL-13 antibody B-B13, and VHh8D4-8 is a humanized heavy chain variable domain of anti IL-4 antibody 8D4-8. 
Bispecifično antitijelo ili njegov bispecifični fragment antitijela koji se specifično veže na IL-13 i IL-4, naznačeno time da navedeno bispecifično antitijelo ili njegov bispecifični fragment antitijela sadrži dva laka lanca sa strukturom N-VLhB-B13-poveznica-VLhBD4-8-CL-C i dva teška lanca sa strukturom N-VHhB-813-poveznica-VHhBD4-8-CH1-CH2-CH3-C, pri čemu VLhB-B13 sadrži sekvencu aminokiseline SEQ ID NO: 1, pri čemu VLh8D4-3 sadrži sekvencu aminokiseline SEQ ID NO: 3, pri čemu VHhB-B13 sadrži sekvencu aminokiseline SEQ ID NO: 2, pri čemu VHh8D4-8 sadrži sekvencu aminokiseline SEQ ID NO: 5, te pri čemu svaka poveznica je peptidna poveznica koja ima sekvencu aminokiseline koja sadrži SEQ ID NO: 6.
Method of claim 4 or 5, wherein the ethanol sample is selected from wine and great musts, alcoholic drinks, beers, fruit juices, honey and other food products, which contain ethanol and/or fermentable sugars. 
Postupak u skladu sa zahtjevom 4 ili 5, naznačen time što je uzorak etanola odabran od vina, mošta, alkoholnih pića, piva, voćnih sokova, meda i drugih prehrambenih proizvoda koji sadrže etanol i/ili fermentabilne šećere.
In other words, the two work banks are switched and operation-tested continually with no interruption in the work operations. 
Drugim riječima, dvije radne banke se prekopčavaju i radno testiraju kontinuirano bez ikakvog prekida radnih operacija.
Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use. 
Oralni tekući pripravci mogu biti u obliku, primjerice, vodenih ili uljnih suspenzija, otopina, emulzija, sirupa ili ljekovitih napitaka, ili mogu biti u obliku suhog proizvoda za pripravu s vodom ili drugim pogodnim vehikulumom, prije upotrebe.
at least one filler in a total amount of 10% to 40 % by weight based on total weight of the tablet, wherein the filler is microcrystalline cellulose; 
najmanje jedno punilo u ukupnoj količini od 10 do 40 masenih postotaka na osnovi ukupne mase tablete, gdje to punilo je mikrokristalna celuloza;
at a predetermined time after step (i), treating the liquid iron with a magnesium containing nodulariser, 
između 2 i 10 minuta nakon koraka (i), obrada tekućeg željeza nodulatorom koji sadrži magnezij,
eluting the rAAV particles bound to the apatite chromatography medium with an elution buffer containing less than 3% (w/v) PEG. 
eluiranje čestica rAAV vezanih na HIC medij s puferom srednje koncentracije, pri čemu pufer srednje koncentracije soli sadrži manje od 0.5M citrata.
The pharmaceutical composition according to Claim 11 for use in therapy. 
Farmaceutski sastav prema zahtjevu 18, naznačen time, da se upotrebljava u liječenju.
A system according to claim 9, wherein the refrigeration system is suitable for use with chlorodifluoromethane (HFC-22) and a refrigerant composition as defined in claim 1 is substituted for HFC-22 in the system. 
Sustav prema zahtjevu 12, naznačen time da je rashladna tvar kako je definirana u zahtjevu 3, te pri čemu je sustav hladnjak koji radi na temperaturi od -26.1 *C (-15%F).
In some embodiments, the polypeptide comprises: (a) a polypeptide having at least about 80% sequence identity to SEQ ID NO:14 or SEQ ID NO:24; and/or (b) a polypeptide having at least about 80% sequence identity to SEQ ID NO:8, SEQ ID NO:28 or SEQ ID NO:32. 
Protutijelo prema zahtjevu 1, zahtjevu 2, ili zahtjevu 4, naznačeno time, da obuhvaća: a) varijabilno područje jakog lanca, koje ima najmanje oko 90% identiteta sekvence od SEQ ID NO:50, SEQ ID NO:14, ili SEQ ID NO:20; 1 b) varijabilno područje slabog lanca, koje ima najmanje oko 90% identiteta sekvence od SEQ ID NO:13 ili SEQ ID NO: 19.
The container according to claim 7 or 8, wherein the container is made of glass. 
Spremnik prema zahtjevu 1 or 2, naznačen time da je spremnik izrađen od stakla.
Generally, cell culture media comprise many components of different categories, such as amino acids, vitamins, salts, fatty acids, and further compounds: Amino acids: For instance, U.S. Pat. No. 6,048,728 (Inlow et al.) discloses that the following amino acids may be used in a cell culture medium: Alanine, Arginine, Aspartic Acid, Cysteine, Glutamic Acid, Glutamin, Glycine, Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenyalanine, Proline, Serine, Tryptophan, Tyrosine, Threonine, and Valine. 
Općenito, mediji za kulturu stanica sadrže mnoge komponente iz različitih kategorija, poput aminokiselina, vitamina, soli, masnih kiselina i slijedećih sastojaka: aminokiseline: Na primjer, US 6,048,728 (Inlow et al.) navodi da se u mediju za kulturu stanica mogu koristiti slijedeće aminokiseline: alanin, arginin, aspartatska kiselina, cistein, glutaminska kiselina, glutamin, glicin, histidin, izoleucin, leucin, lizin, metionin, fenilalanin, prolin, serin, triptofan, tirozin, treonin i valin.
The discharge, as indicated by the arrow 110, takes place between the tip of the high-voltage electrode 107 and the tip of the ground shell 106 . FIG. 
Sustav prema zahtjevu 7, pri čemu su prvi vrh prve elektrode (2b.1) i drugi vrh druge elektrode (2b.2) ravni.
A compound according to claim 1, which is an acid addition salt of (E)-3-[1-(4-dimetylaminomethyl-benzenesulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide with any add selected from the group consisting of benzenesulfonic acid, ethanesulfonic acid, glutamic acid, malonic acid, naphthalene-2-sulfonic acid, salicyclic acid, capronic acid, glutaric acid and palmitic acid, or a hydrate thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je kiselinska adicijska sol (£)-3-[1-(4- dimetilaminometilbenzensulfonil)-1€-pirol-3-11]-N-hidroksiakrilamida s bilo kojim add kojeg se bira iz skupine koju čine benzensulfonska kiselina, etansulfonska kiselina, glutaminska kiselina, malonska kiselina, naftalen-2sulfonska kiselina, salicilna kiselina, kapronska kiselina, glutarna kiselina i palmitinska kiselina, ili njegov hidrat.
The active substance compositions according to the invention are preferably administered in the form of compositions for inhalation delivered with the help of inhalers, especially dry powder inhalers, however, any other form or parenteral or oral application is possible. 
Pripravci djelatnih tvari sukladno predmetnom izumu poželjno se daju u obliku pripravaka za inhalacije koje se isporučuju putem inhalatora, osobito inhalatora za suhi prašak, iako je moguć bilo koji drugi oblik ili parentcralna ili peroralna primjena.
The compound or salt for use according to claim 1, wherein the compound is selected from: 
Spoj prema zahtjevu 1, naznačen time da da je odabran iz skupne koja sadrži:
step 2: separation of both diastereoisomers of the tartrate salt, 
korak 2: razdvajanje oba diastereoizomera tartratne soli,
Lubricate the granules of step (III) with croscarmellose sodium, colloidal silicon dioxide, microcrystalline cellulose and magnesium stearate and mix in a cage blender. 
(IV)Navlažite granule koraka (III) s kroskarmeloza natrijem, koloidnim silicij dioksidom, mikrokristalnom celulozom i magnezij steratom te miješajte u zatvorenom mikseru.
The crude residue was dissolved in 41 mL of anisole at room temperature. 
Postupak iz patentnog zahtjeva 2, u kome se kristalizacija događa na sobnoj temperaturi.
7- t -Butoxyiminomethyl-camptothecin is the most preferred combination partner (a). 
Farmaceutski oblik koji sadrži (a) 7-t-butoksiiminometilkamptotecin; i (b) cis-Platin za sekvencijalnu uporabu.
wherein the conveyor system is for conveying the wood pieces one-by-one onto the loading hatch in a predetermined orientation; 
gdje je transportni sustav (5, 7) namijenjen transportiranju komada drva pojedinačno na otvor za punjenje (9) u zadanoj orijentaciji;
Wireless communication apparatus and reference signal generating method 
BEŽIČNI KOMUNIKACIJSKI UREĐAJ I METODA GENERIRANJA REFERENTNOG SIGNALA
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fludioxonil. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) klorotalonil.
Another embodiment of this invention relates to compounds wherein K is N and L and M are each C. 
Spoj u skladu s patentnim zahtjevom 1, gdje K je N, asvaki od LiM je C.
Process for bacterial stabilizing an aqueous preparation, said preparation comprising at least one natural calcium carbonate, synthetic, precipitated calcium carbonate, kaolin, talcum, aluminium hydroxide, aluminium silicate, titanium dioxide or mixtures thereof and at least one strain of bacteria selected from the group consisting of Methylobacteria and Pseudomonas which is resistant to, tolerant to and/or degrade aldehyde-releasing biocides and/or biocides with one or more aldehyde groups in absence of lithium ions, wherein the process comprises the steps of: adding to the aqueous preparation one or more aldehyde-releasing biocides and/or biocides with one or more aldehyde groups in an amount such that the total amount of aldehyde-releasing biocides and/or biocides with one or more aldehyde groups in the aqueous preparation is from 250 ppm to 5000 ppm, calculated relative to the water in the preparation; 
Uporaba sastava koja obuhvaća: jedan ili više biocida koji otpušta aldehid i/ili biocida s jednom ili više aldehidnih skupina u tolikoj količini da je ukupna količina biocida koji otpuštaju aldehid i/ili biocida s jednom ili više aldehidnih skupina u vodenom pripravku od 250 ppm do 5000 ppm, izračunata u odnosu na težinu vode u pripravku, i barem jedan izvor u vodi topljivih litijevih spojeva u količini tolikoj da je ukupna količina otopljenog litija u vodenom pripravku od 1000 do 3000 ppm, izračunato u odnosu na težinu vode u pripravku, pri čemu je u vodi topljivi litijev spoj polimerna sol litija izabrana od Li2Na2polifosfata ili litij-natrij heksametafosfata;
A compound of Formula I: wherein: 
[image] sa spojem Formule IX
The amorphous pellets were subjected to a microscopic analysis, the result of which is shown in FIG. 
Iz amorfnih peleta napravljena je mikroskopska analiza prikazana na Slici 1.
providing one or more rails (1, 3) between the drawer and the furniture body, 
- < pripremanje jedne tračnice ili više tračnica (1, 3) koje se nalaze između ladice 1 tijela namještaja,